ASTRA Therapeutics
Recent Finacing
Seed
Recent Raise
$9.6M
ASTRA Therapeutics develops species-specific, tubulin-targeting veterinary parasiticides using its ParaX platform to generate Parabulins—nanomolar-potent, multi-class drug leads targeting coccidia, heartworm, and other parasites.
Highlights
Focus Areas
Health Care
Therapeutics
Recent Investors
Financials
$9.6M
Total Raised
1
Funding round
5
Investors